Business Wire

NV-1NCE

5.1.2023 15:31:41 CET | Business Wire | Press release

Share
1NCE expands IoT software business with launch of 1NCE OS

1NCE, a global IoT connectivity and software company, today announced the creation of its software business unit in conjunction with the Consumer Electronics Show launch of 1NCE OS – IoT software offering powerful developer tools and device control to make IoT even more accessible.

The software tools are an integral part of 1NCE’s Lifetime Flat service and are available complimentary to 1NCE customers.

1NCE OS is a foundational element of the company’s ambitious goal: to cement 1NCE’s standing as the preeminent destination for accessible IoT. It’s designed for easy integration of 1NCE’s connectivity and software features into IoT projects of any scale, for new and existing projects alike. Using 1NCE OS for device and cloud integration, customers can accelerate time-to-market for IoT projects by months. One of 1NCE’s core principles is that customer data isn’t to be monetized and used to sell additional services. Instead, 1NCE is transparent about turning data into tools that are included in the global lifetime flat rate.

Features available at launch:

  • Device Authentication: The process of setting up a secure and automated solution usually requires a complicated and error-prone onboarding process. 1NCE OS makes it simple: customers just solder the secure SIM into their device just like any other hardware piece and that’s it – delivering better authentication and integration of uniquely identified devices into IoT projects.
  • IoT Integrator: Reliably connecting devices to the cloud can be complex, but 1NCE’s managed protocol translation uses open industry standards (UDP, CoAP, LwM2M, AWS IoT Core, Webhooks) to give customers the free and full flexibility they demand.
  • Device Inspector: The time-intensive and costly process of sending technicians into the field to monitor and service devices is significantly reduced using advanced remote access to device states and recent telemetry.
  • Device Locator: Network based positioning helps users locate devices even without GPS.
  • Energy Saver: The inherent challenges of battery-powered devices make power usage a high priority, and 1NCE’s optimized payload transmission can increase battery life by up to 50 percent.

Fredrik Stålbrand of Berg Insights said: “1NCE OS and 1NCE’s product roadmap look very compelling. Our view is that the IoT connectivity market will increasingly move towards digitalized sales and delivery. SIMs will be pre-installed in chipsets, while connectivity management is increasingly being controlled by SaaS applications. Customers expect simple, digital experiences throughout the product lifecycle. 1NCE is clearly at the forefront of this development.”

Ivo Rook, Chief Operating Officer at 1NCE: “1NCE flips the script for customers – we don’t monetize their data for a few extra dollars because our customers’ data is theirs and theirs alone. 1NCE’s move into software allows us to boost our customers’ ideas not just when they need connectivity, but from the outset of their projects and all the way through a device’s lifecycle. IoT connectivity and software for life for a single fee, and that’s it.”

Fifty percent of failed IoT projects falter in the pilot stage. For new IoT projects, 1NCE makes it easy to experiment early without major expenditures that can kill a project. Customers connect sensors across the globe at a fraction of the cost of the traditional price of network operators, and now with 1NCE OS, they gain access to software tools that accelerate time-to-market without vendor lock-in or paying for unnecessary features packaged into most IoT platforms. And for IoT projects that are already up and running, 1NCE’s combination of connectivity and software delivers trusted, production-grade solutions for continuous improvement and optimization.

The majority of IoT projects require multinational deployments, but few network operators have the capability to truly meet cross-border demands. The 1NCE Lifetime Flat service is industry-disruptive but simple: for $10/€10, customers can deploy, connect, and manage IoT sensors across the world for as little as a dollar per year per device. More than 10,000 customers worldwide already trust 1NCE with more than 15 million managed connections.

The company’s ability to deliver affordable and reliable IoT, and its rapid global expansion to 153 markets from 106 at the beginning of the year, helped 1NCE earn two prestigious awards recently: Honorable Mention on Fast Company’s list of the Next Big Things in Tech and top prize for the most outstanding use case in “innovative IoT” (in partnership with Flashnet) at Light Reading’s 18th annual Leading Lights.

More information about 1NCE OS can be found here and customers can get started with 1NCE at the company’s online shop and the AWS Marketplace. Customer support is available in 14 languages.

About 1NCE

1NCE is the only connectivity and software company providing IoT at a lifetime global flat rate. Our mission is to deliver true cross-border, future-proof IoT without uncertainty or hassle over the lifetime of a device. In 150+ countries, 1NCE turns connectivity into electricity ready for consumption – opening the world of IoT to innovators who will dramatically improve the environment, cities, healthcare, public safety, the supply chain and more. The company, founded in 2017 by CEO Alexander P. Sator together with Deutsche Telekom AG, is headquartered in Cologne, Germany and has 250+ staff across 20 countries. Learn more online and follow 1NCE on Twitter, LinkedIn and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005461/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye